Clinical Trials Logo

Clinical Trial Summary

Efficacy and safety of epigallocatechin-3-gallate (EGCG) in patients with cardiac amyloid light-chain (AL) amyloidosis. Evaluation of clinical efficacy of EGCG intake using a pretest posttest comparison of left ventricular amyloid mass (g/m2) measured by cardiac MRI.


Clinical Trial Description

n/a


Study Design


Related Conditions & MeSH terms


NCT number NCT02015312
Study type Interventional
Source University Hospital Heidelberg
Contact
Status Completed
Phase Phase 2
Start date April 2013
Completion date October 11, 2017

See also
  Status Clinical Trial Phase
Active, not recruiting NCT05996406 - Venetoclax and Dexamethasone for Newly Diagnosed Light-Chain Amyloidosis With Translocation (11;14) Phase 2
Withdrawn NCT05692908 - An Open-Label Study of the Safety of an Anti-CD38 Antibody Drug Conjugate (STI-6129) in Patients With AL Amyloidosis Phase 1
Withdrawn NCT04943302 - Isatuximab and Bendamustine in Systemic Light Chain Amyloidosis Phase 2
Not yet recruiting NCT06097832 - Study of NXC-201 CAR-T in Patients With Light Chain (AL) Amyloidosis Phase 1
Recruiting NCT05486481 - Venetoclax, Daratumumab, and Dexamethasone for Systemic Light-Chain Amyloidosis With Translocation (11;14) (ALTITUDE) Phase 1/Phase 2
Recruiting NCT06376214 - Daratumumab for Patients With Light Chain Amyloidosis N/A
Recruiting NCT04973137 - A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis Phase 3
Recruiting NCT04316442 - Study of the Safety and Efficacy of STI-6129 in Patients With Relapsed or Refractory Systemic AL Amyloidosis Phase 1/Phase 2